DOI: https://doi.org/10.7705/biomedica.v38i0.3458

La tuberculosis en la era del tratamiento con fármacos inhibidores del factor de necrosis tumoral alfa: ¿por qué persiste el riesgo?

John-Leonardo Torres-Castiblanco, Jorge Alberto Carrillo, Daniel Hincapié-Urrego, Adriana Rojas-Villarraga

Resumen


La artritis reumatoidea es una enfermedad crónica de carácter autoinmunitario caracterizada principalmente por el compromiso inflamatorio de las articulaciones cartilaginosas. Se han desarrollado múltiples tratamientos farmacológicos para controlar el avance de la artritis reumatoidea, entre ellos, los fármacos antirreumáticos modificadores de la enfermedad, además de nuevos esquemas terapéuticos con inhibidores del factor de necrosis tumoral alfa, con resultados clínicos satisfactorios. Sin embargo, el uso de tales medicamentos no resulta inocuo, ya que se los ha asociado con diversos efectos
secundarios, especialmente, infecciones como la tuberculosis, lo cual exige la aplicación de pruebas de tamización antes de utilizarlos.
Se reporta el caso de una paciente de 58 años de edad con artritis reumatoidea de seis años de evolución, que después de recibir tratamiento con uno de estos fármacos, el infliximab, desarrolló tuberculosis diseminada, cuyo diagnóstico se confirmó mediante radiología e histopatología. No se emplearon pruebas de detección de la tuberculosis latente antes de prescribirle el infliximab.
Las pruebas de tamización para tuberculosis deben emplearse de forma rutinaria, con el fin de detectar aquellos pacientes con tuberculosis latente, ya que es la única manera de determinar si se requiere profilaxis antituberculosa antes de administrar dichos fármacos, hecho que marca la diferencia cuando se busca disminuir la incidencia de tuberculosis y la consecuente morbimortalidad.


Palabras clave


Mycobacterium tuberculosis; tuberculosis; diagnóstico; artritis reumatoidea; factor de riesgo; factor de necrosis tumoral alfa; terapia biológica; infliximab; Colombia

Texto completo:

PDF (English) HTML (English)

Referencias


1. Anaya JM, Shoenfeld Y, Rojas-Villarraga A, Levy RA, Cervera R. Autoimmunity from bench to bedside. First edition. Bogotá: Universidad del Rosario; 2013. p. 381-2.
2. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. https://doi.org/10.1136/ard.2009.123919
3. Gorter SL, Bijlsma JM, Cutolo M, Gómez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;69:1010-14. https://doi.org/10.1136/ard.2009.127332
4. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: Past, present and future. Int Immunol. 2015;27:55-62. https://doi.org/10.1093/intimm/dxu102
5. Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14:503-9. https://doi.org/10.1016/j.autrev.2015.01.011
6. Vivar N, van Vollenhoven RF. Advances in the treatment of rheumatoid arthritis. F1000Prime Rep. 2014;6:31. https://doi.org/10.12703/P6-31
7. Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79-99. https://doi.org/10.2147/DHPS.S28801
8. Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Infection risk associated with anti-TNF-α agents: A review. Expert Opin Drug Saf. 2015;14:571-82.
https://doi.org/10.1517/14740338.2015.1009036
9. Joshi P, Dhaneshwar SS. An update on disease modifying antirheumatic drugs. Inflamm Allergy Drug Targets. 2014;
13:249-61. https://doi.org/10.2174/187152811304140915152102
10. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008;117:244-79. https://doi.org/10.1016/j.pharmthera.2007.10.001
11. Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am. 2011;25:117-38. https://doi.org/10.1016/j.hoc.2010.11.009
12. Solovic I, Sester M, Gómez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J. 2010;36:1185-206. https://doi.org/10.1183/09031936.00028510
13. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4:S22-8. https://doi.org/10.1186/ar549
14. Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2:137-47.
15. Wallis RS. Tumour necrosis factor antagonists: Structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601-11. https://doi.org/10.1016/S1473-3099(08)70227-5
16. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol. 2003;98:1315-24. https://doi.org/10.1111/j.1572-0241.2003.07457.x
17. Rosenblum H, Amital H. Anti-TNF therapy: Safety aspects of taking the risk. Autoimmun Rev. 2011;10:563-8. https://doi.org/10.1016/j.autrev.2011.04.010
18. Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A. Cardiovascular safety of anti-TNFalpha therapies: Facts and unsettled issues. Autoimmun Rev. 2011;10:631-5. https://doi.org/10.1016/j.autrev.2011.04.014
19. Xie X, Li F, Chen J-W, Wang J. Risk of tuberculosis infection in anti-TNF-α biological therapy: From bench to bedside. J Microbiol Immunol Infect. 2014;47:268-74. https://doi.org/10.1016/j.jmii.2013.03.005
20. Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-α reagents. Pediatr Rheumatol Online J. 2014;12:45. https://doi.org/10.1186/1546-0096-12-45
21. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602-10. https://doi.org/10.1038/ncprheum0336
22. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous
infections due to tumor necrosis factor blockade: Correction. Clin Infect Dis. 2004;39:1254-5. https://doi.org/10.1086/424455
23. World Health Organization. Tuberculosis. First edition. Accessed: 12 de octubre de 2015. Available from: http://www.who.int/mediacentre/factsheets/fs104/en/
24. World Health Organization. Tuberculosis, Colombia 2012. First edition. Accessed: 25 de noviembre de 2015. Available from: https://extranet.who.int/sree/Reports?op=Replet&name=
%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCou
ntryProfile&ISO2=CO&LAN=EN&outtype=html
25. Shim TS. Diagnosis and treatment of latent tuberculosis
infection due to initiation of anti-TNF therapy. Tuberc Respir Dis (Seoul). 2014;76:261-8. https://doi.org/10.4046/trd.2014.76.6.261
26. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522-8. https://doi.org/10.1136/ard.2009.118935
27. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884-94. https://doi.org/10.1002/art.24632
28. Lee H, Park HY, Jeon K, Jeong B-H, Hwang J-W, Lee J, et al. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS One. 2015;10:e0119260. https://doi.org/10.1371/journal.pone.0119260
29. Rojas-Villarraga A, Agudelo CA, Pineda-Tamayo R, Porras A, Matute G, Anaya JM. Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile? Biomédica. 2007;27:159-71. https://doi.org/10.7705/biomedica.v27i2.212
30. Centers for Disease Control and Prevention. Tuberculosis
associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004;53:683-6.
31. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-72.https://doi.org/10.1002/art.21043
32. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis. 2003;62:791.
https://doi.org/10.1136/ard.62.8.791
33. Fonseca JE, Canhão H, Silva C, Miguel C, Mediavilla MJ, Teixeira A, et al. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: The Portuguese experience. Acta Reumatol Port. 2006;31:247-53.
34. Caballero CV, Pinzón L. Artritis reumatoide tratada con inhibidores del factor de necrosis tumoral α (Anti-TNF-α) y tuberculosis pulmonar. Salud Uninorte. 2006;22:29-39.
35. Hidalgo P, Echeverri J, Gutiérrez JM. Tuberculosis pleural asociada con adalimumab, en un paciente con artritis reumatoide. Infectio. 2010;14:47-54. https://doi.org/10.1016/S0123-9392(10)70092-8
36. Londoño P, Fernández D, Salazar J, Saiibi D, Molina J, Valle R, et al. Cambio en la capacidad funcional, calidad de vida y actividad de la enfermedad, en un grupo de pacientes colombianos con artritis reumatoide refractaria (sic) al tratamiento convencional, que recibieron terapia con infliximab como medicamento de rescate. Rev Fac Med. 2009;17:40-9.
37. Machado J, Moncada JC, Pineda R. Perfil de utilización de los anti-factor de necrosis tumoral en pacientes de Colombia. Biomédica. 2011;31:250-7. https://doi.org/10.7705/biomedica.v31i2.319
38. Martínez JB, Medina Y, Parga R, Restrepo JF, Iglesias A, Rondón F. Reactivación de tuberculosis pulmonar (TBC) con el uso de antagonistas del factor de necrosis tumoral alfa (FNTa) en artritis reumatoide. A propósito de un caso. Rev Colomb Reumatol. 2005;12:54-61.
39. Muñoz OM, Hurtado M, Fernández D, Hidalgo P, Gutiérrez JM. Conversión de tuberculosis latente en un grupo de pacientes tratados con terapia biológica en una unidad de Reumatología. Rev Colomb Neumol. 2014;26:116-22.
40. Insuasty JS, Bolívar A, Calvo LS, Roberto SL. Tuberculosis peritoneal simulando cáncer de ovario. Acta Med Colomb. 2014;39:383-7.
41. Vega J, Pinto LF, Muñoz C, Márquez JD, Rodríguez LM, Velázquez CJ. Infecciones en pacientes con artritis reumatoide:
medicamentos moduladores de la respuesta biológica versus fármacos modificadores de la enfermedad. Seguimiento a un año. Rev Colomb Reumatol. 2013;21:27-34.
42. Wang MH, Liu X, Shen B. Disseminated tuberculosis in a
patient taking anti-TNF therapy for Crohn’s disease. ACG Case Reports J. 2015;3:45-8. https://doi.org/10.14309/crj.2015.97
43. Tanaka T, Sekine A, Tsunoda Y, Takoi H, Lin S-Y, Yatagai Y, et al. Central nervous system manifestations of tuberculosis-associated immune reconstitution inflammatory syndrome during adalimumab therapy: A case report and review of the literature. Intern Med. 2015;54:847-51. https://doi.org/10.2169/internalmedicine.54.2828
44. van der Have M, Belderbos TD, Fidder HH, Leenders M, Dijkstra G, Peters CP, et al. Screening prior to biological therapy in Crohn’s disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Dig Liver Dis. 2014;46:881-6. https://doi.org/10.1016/j.dld.2014.07.006
45. Raval A. Brief communication: Characteristics of spontaneous
cases of tuberculosis associated with infliximab. Ann Intern Med. 2007;147:699-702. https://doi.org/10.7326/0003-4819-147-10-200711200-00006
46. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med. 2001;345:1098-104. https://doi.org/10.1056/NEJMoa011110.
47. Elbek O, Uyar M, Aydin N, Börekçi S, Bayram N, Bayram H, et al. Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin Rheumatol. 2009;28:421-6. https://doi.org/10.1007/s10067-008-1067-x
48. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid
use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19-26. https://doi.org/10.1002/art.21705
49. Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials. Ann Med. 2014;46:547-54. https://doi.org/10.3109/07853890.2014.941919
50. Brode SK, Jamieson FB, Ng R, Campitelli MA, Kwong JC, Paterson JM, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70:677-82. https://doi.org/10.1136/thoraxjnl-2014-206470
51. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNFalpha treatments. Rheumatology (Oxford). 2005;44:1205-6. https://doi.org/10.1093/rheumatology/kei103
52. Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly. 2007;137:620-2.
53. Diel R, Hauer B, Loddenkemper R, Manger B, Krüger K. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic disease. Pneumologie. 2009;63:329-34. https://doi.org/10.1055/s-0029-1214673
54. Hur Y-G, Kang YA, Jang S-H, Hong JY, Kim A, Lee SA, et al. Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects. J Infect. 2015;70:346-55. https://doi.org/10.1016/j.jinf.2014.10.019
55. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res. 2006;7:56. https://doi.org/10.1186/1465-9921-7-56
56. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET Study. Am J Respir Crit Care Med. 2014;190:1168-76. https://doi.org/10.1164/rccm.201405-0967OC
57. Quintana-López G, Grillo-Ardila C, Méndez P, Vallejo M, Guevara O, Velásquez C, et al. Guía de práctica clínica para la detección temprana, diagnóstico y tratamiento de la artritis reumatoide. Primera edición. Bogotá, D.C.: Ministerio de Salud y Protección Social; 2014.
58. Debeuckelaere C, De Munter P, van Bleyenbergh P, De Wever W, van Assche G, Rutgeerts P, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis. 2014;8:550-7. https://doi.org/10.1016/j.crohns.2013.11.008
59. Çekiç C, Aslan F, Vatansever S, Topal F, Yüksel ES, Alper E, et al. Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy. Ann Gastroenterol. 2015;28:241-6.
60. Bernal JA, Andrés M, Jovaní V, García-Sevila R, Begazo A, Vela P. Primary tuberculosis infection in patients treated with tumor necrosis factor-alpha antagonists and a negative initial screening. Reumatol Clin. 2016;12:81-4. https://doi.org/10.1016/j.reuma.2015.04.001
61. Smith MY, Attig B, McNamee L, Eagle T. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union. Int J Tuberc Lung Dis. 2012;16:1168-73. https://doi.org/10.5588/ijtld.12.0029
62. Ferreira BA, Ribeiro S, Meireles J, Correia A, Duarte R. Tuberculosis screening and compliance rate with guidelines among northern Portuguese hospitals prescribers of anti-TNF therapy. Rev Port Pneumol. 2014;21:99-101. https://doi.org/10.1016/j.rppnen.2014.09.008


Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Revista Biomédica -  https://doi.org/10.7705/issn.0120-4157
ISSN 0120-4157

Instituto Nacional de Salud
INSTITUTO NACIONAL DE SALUD
Avenida Calle 26 No. 51-20
Apartado aéreo 80334 y 80080
Bogotá, D.C., Colombia, S.A.
Teléfono: 05712207700 Ext. 1386
Correo electrónico: biomedica@ins.gov.co